Moody Lynn & Lieberson LLC Buys 861 Shares of Stryker Corporation $SYK

Moody Lynn & Lieberson LLC raised its stake in shares of Stryker Corporation (NYSE:SYK) by 1.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 87,798 shares of the medical technology company’s stock after purchasing an additional 861 shares during the quarter. Stryker accounts for about 2.0% of Moody Lynn & Lieberson LLC’s investment portfolio, making the stock its 17th biggest position. Moody Lynn & Lieberson LLC’s holdings in Stryker were worth $34,736,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in SYK. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the 1st quarter worth approximately $32,000. City Holding Co. lifted its position in Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares during the period. Ridgewood Investments LLC boosted its stake in Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new stake in Stryker in the 1st quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker in the 1st quarter valued at $40,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of Stryker stock opened at $368.83 on Monday. The firm has a 50 day simple moving average of $385.71 and a 200 day simple moving average of $379.18. The firm has a market cap of $141.01 billion, a P/E ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.During the same quarter in the prior year, the firm posted $2.81 earnings per share. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is presently 44.50%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SYK. Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Needham & Company LLC upped their price objective on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. BTIG Research reissued a “buy” rating on shares of Stryker in a report on Monday, July 14th. Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target on the stock. Finally, Rothschild Redb upgraded Stryker to a “hold” rating in a research note on Thursday, September 18th. Fourteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $430.33.

Insider Activity

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.